Introduction
Pulmonary sarcoidosis is a disorder ofthe lower respiratory tract characterized by chronic inflammation, granuloma formation, and, in some individuals, parenchymal fibrosis (1) (2) (3) (4) . Together, these processes derange the alveoli, airways, and blood vessels, consequently impairing the ability of the lung to exchange gas in a normal fashion (5, 6) . As with the other interstitial lung disorders, it is recognized that the inflammation precedes the other abnormalities that characterize this disorder (7, 8) .
The inflammation of active pulmonary sarcoid is dominated by an accumulation of T helper lymphocytes in the lung parenchyma (9, 10 [1962] [1963] [1964] [1965] [1966] [1967] [1968] [1969] [1970] altering the intimate relationships between air and blood (1 1).
Second, the T cell populations are activated and spontaneously release monocyte chemotactic factor and interferon-y, mediators that recruit and activate mononuclear phagocytes, respectively, which are events that are early steps in the process ofgranuloma formation (12, 13) . In this context, an understanding ofthe pathogenesis of pulmonary sarcoid is intimately linked to understanding the processes directing the accumulation ofT lymphocytes in the lower respiratory tract of individuals with active disease. Relevant to this question, it is known that the T lymphocytes recovered from the lungs of these patients are spontaneously proliferating and spontaneously releasing interleukin 2 (IL-2),' the T cell growth factor (14, 15) . Thus, although the stimulus that initiates the process is unknown, the IL-2-releasing lung T cells are thought to be responsible for maintaining the T cell alveolitis and thus maintaining the disease in an active state.
The present study expands upon this concept by determining those T cell subsets that are responsible for the spontaneous release of IL-2 in the lower respiratory tract ofthese individuals. The data demonstrate that the IL-2-releasing cells are the lung Leu3+ (helper/inducer) T lymphocytes expressing a high intensity of HLA-DR antigens on their surfaces. Because this is the same subset of T lymphocytes that help in vitro proliferation of T cells in response to antigens, these observations lend credence to the concept that the T cell alveolitis of sarcoid is an exaggeration of the normal processes of T cell activation.
Methods

Study population
Normals. The control population consisted of 22 normal individuals, including 15 men and 7 women, with a mean age of 26±5 yr (all data are presented as mean±standard error ofthe mean). None had a history of lung disease and none had evidence of lung disease by physical examination, chest X-ray, and pulmonary function tests. All were nonsmokers; no control was taking medication at time of the study.
Patients with sarcoidosis. The diagnosis of pulmonary sarcoidosis was established in 40 individuals using previously described criteria (2) (19) . Thereafter, the cells were handled in a manner identical to the lung cells.
Monoclonal antibodies
Fluorescein, biotin, or phycoerythrin-conjugated mouse monoclonal antibodies Leu4 (T lymphocytes [20] ), Leu3 (helper/inducer T-cell subset [21] ), Leu2 (suppressor/cytotoxic T-cell subset [21 ] ) and the anti-HLA-DR mouse monoclonal antibody L243 (HLA-DR framework [22] Flow cytometry (27) was used to separate Leu3+ and Leu2+ lung lymphocytes and Leu3+ lung lymphocytes into "high-intensity DR" and "low-intensity DR" subpopulations. Lung T lymphocytes, obtained from bronchoalveolar lavage cells depleted of adherent cells through nylon wool columns, were incubated for 30 min on ice at a concentration of 107/ml in 5-ml round-bottomed tubes (Falcon Labware) with 20,ug/ ml of fluorescein-conjugated Leu3 and phycoerythrin-conjugated L243 (anti-HLA-DR) in "sheath medium" (HBSS without phenol red [M. A. Bioproducts], 100 U/ml penicillin, 100 Mg/ml streptomycin (M. A. Bioproducts], and 1% FCS [Biofluids]). In some experiments, lung T lymphocytes were reacted with fluorescein-conjugated Leu3 and phycoerythrin-conjugated Leu2 to separate Leu3+ and Leu2+ lung lymphocytes. Cells were then washed two times, resuspended in "sheath medium" and separated using a FACS II (Becton, Dickinson & Co., FACS Systems, Sunnyvale, CA) operated using an argon laser at the wavelength of 488 nm to excite fluorescein and phycoerythrin. Forward angle light scatter was used to discriminate viable lymphocytes from dead cells and the small numbers of mononuclear phagocytes present (27) . Sorted cells were collected in RPMI-1640 without phenol red (M. A. Bioproducts) on ice and reanalyzed through the FACS II to assess viability, purity, and HLA-DR fluorescence intensity of the sorted cell populations. After centrifugation, cells were resuspended in culture medium for use. Viability, determined by forward angle light scatter, was always >95%.
Quantification ofIL-2 release IL-2 release by lung T cells was assessed as previously described (14) . Briefly, lung mononuclear cells or purified lymphocytes were cultured for 24 h in a 5% CO2 humidified incubator at 37°C, in RPMI-1640 (M. A. Bioproducts) containing 1% FCS, 0.2 mM glutamine (M. A. Bioproducts), 100 U/ml penicillin, and 100 Mg/ml streptomycin at a concentration of 106 cells/ml in 24-well plates (Costar, Cambridge, MA).
As a control, parallel cultures were incubated with 5 Mg/ml concanavalin A (Sigma Chemical Co.). At the end ofthe culture period the supematants were collected by centrifugation and stored at -20°C until assayed for IL-2 activity by their ability to stimulate the incorporation of [3H]thymidine (Amersham International, Amersham, UK) by IL-2-dependent CT6 murine T-lymphocytes. IL Individuals evaluated (n) 22 40 Evaluatio'ns (n) 22 57 Lavage fluid recovered %)47±3 57±2 Expression of HLA-DR molecules on the surface of lung Leu3+ cells in sarcoidosis. Consistent with the concept that the lung T cells in sarcoidosis are "activated," two-color immunofluorescence analysis demonstrated that strikingly increased proportions of lung Leu3+ T lymphocytes in the sarcoid lung expressed HLA-DR molecules (Table I) . In these individuals, the proportion of Leu3+ cells that reacted with the anti-HLA-DR monoclonal antibody was markedly higher (30±3% of Leu3+ cells) than the proportion of.lung Leu3+ lymphocytes in normals that were DR+ (6±1% of Leu3+ cells, P < 0.01 compared to sarcoid). In the sarcoid lung Leu2+ T-cells also expressed surface HLA-DR (22±3% of Leu2 cells; Table I ). However, owing to the significantly lower numbers of Leu2+ cells in the lower respiratory tract of these patients, the burden of Leu2+DR+ cells in the sarcoid lung (3±1% ofcells recovered) was significantly lower than that of Leu3+DR+ cells (13±1% of cells recovered; P < 0.001 compared to Leu2). In addition to HLA-DR, lung 3+ T cells in sarcoidosis also expressed the IL-2 receptor. Although 6±1% of Leu3+ cells were Tac+ (Table  I) Consistent with the fact that IL-2 was being spontaneously released in the lungs of those individuals with large numbers of Leu3+DR+ lymphocytes in the lower respiratory tract, the proportion of Leu3+DR+ T cells in the sarcoid lung correlated with the total proportions oflung lymphocytes recovered (those individuals with Leu3+DR+ > 18% had lymphocytes representing 57±3% of cells recovered; those with Leu3+DR+ s 18% had lymphocytes representing 35±3%, P < 0.01). Furthermore, the Leu3+DR+ > 18% group had a Leu3+ to Leu2+ ratio of 10±2 to i whereas the Leu3+DR+ . 18% group had a Leu3+ to Leu2+ ratio of 3±1 to 1 (P < 0.01). The expansion of Leu3+DR+ lung T cell proportions in the sarcoid lung was also found in individuals with worse pulmonary function; the vital capacity and diffusing capacity (DLCO) were significantly lower in patients with proportions of Leu3+DR+ cells > 18% than those with . 18% (P < 0.0 i). To directly determine whether the Leu3+ T lymphocytes that express the activation antigen HLA-DR in the lower respiratory tract of sarcoid patients were the functionally activated T cells that spontaneously release IL-2, the spontaneous release of IL-2 was evaluated in Leu3+ highintensity DR and Leu3+ low-intensity DR sarcoid lung T lymphocytes separated by flow cytometry. The separated cells obtained were highly purified Leu3+ lymphocytes with an insignificant contamination of other cell types (Fig. 3, E-F) . Analysis with the flow cytometer demonstrated that both Leu3+ highintensity DR and Leu3+ low-intensity DR subpopulations contained 98±1 Leu3+ viable lymphocytes. Flow cytometric evaluation of the separated lung lymphocyte Leu3+ population demonstrated that HLA-DR proteins were expressed on the cell surfaces in varying intensity, consistent with known observations of activated T-cells (29) (30) (31) (32) . In this context, the Leu3+DR+ population was observed as a skewed peak ofDR intensity (Figs.  3 A-C) , which was separated into a high-intensity DR and lowintensity DR population by setting appropriate windows (Fig. 3  D) . Analysis of the sorted populations demonstrated that the mean fluorescence channel ofthe high-intensity DR population was 21±1 while the mean fluorescence channel of the low-intensity DR population was 13±1 (P < 0.01). Evaluation of the size distribution of the high-intensity DR and low-intensity DR lung Leu3+ lymphocytes by forward angle light scatter showed no significant difference (P > 0.05), consistent with the concept that size alone could not explain the different intensity of DR expression on the sorted populations.
Analysis Thus, the expression of a high intensity of HLA-DR surface molecules characterized the subpopulation of functionally activated Leu3+ T lymphocytes in the sarcoid lung that were spontaneously releasing the T cell growth factor. These observations are consistent with the concept that the accumulation and increased density offunctionally activated Leu3+HLA-DR+ lung T lymphocytes in sarcoidosis may play a major role in expanding and maintaining the alveolitis by promoting proliferation and expansion oflymphocyte numbers through the augmentation of IL-2 concentration in the alveolar milieu.
Discussion
Pulmonary sarcoidosis is characterized by the accumulation of large numbers of T lymphocytes in the lower respiratory tract (9, 10) . Unlike resting T cells, these sarcoid lung T cells are actively releasing IL-2, the T cell growth factor ( 14, 15) (40) , and interferon-y ( 13) , a 20,000-25,000-D protein (41) that can contribute to the activation of mononuclear phagocytes (42) . Together, these mediators likely play an important role in the local aggregation of mononuclear phagocytes in the lung parenchyma into granulomata, space-occupying lesions that, if present in critical regions of the alveolar, bronchiolar, and/or vascular walls, contribute to altering lung function.
Role ofIL-2 in the accumulation oflung T lymphocytes in sarcoidosis. T lymphocytes recovered from the lungs ofpatients with sarcoidosis are spontaneously releasing IL-2, suggesting that these cells are the driving force for the T cell proliferation ongoing in the lower respiratory tract, and hence for the chronic accumulation oflung T cells that characterize individuals with active disease. Several lines of evidence support this conclusion.
(a) Sarcoid lung lymphocytes proliferate at an increased rate compared with normal lung lymphocytes (14, 15, 33, 34) .
(b) The release of IL-2 by sarcoid T cells is compartmentalized in that it is confined to sites of disease (e.g., lung) and is not observed in blood (14, 15) .
(c) There is an increase in the total numbers ofLeu3+Tac+ (IL-2 receptor) T cells in the lungs of patients with sarcoid (43 (37, 45, 46 (57) . The concept that the immune response may compartmentalize at the site of the activation stimulus is consistent with the observations ofthe compartmental accumulation of T cells in the lung in berylliosis (58, 59 ) and hypersensitivity pneumonitis (56) , T cells in the lesions ofleprosy (39, 54), activated T cells in the cerebrospinal fluid of individuals with multiple sclerosis (60) , in synovial fluid of patients with rheumatoid arthritis (61) , and the salivary glands of patients with Sjogren's syndrome (62) .
Secondly, although all T cells are capable of proliferating, the fact that only Leu3+ T cells accumulate in the sarcoid lung is consistent with the concept that the localized stimulus that activates the T cells is specific for the Leu3+ subset. In this regard, because activated Leu3+ and Leu2+ cells can proliferate in response to IL-2 (52, 63, 64) , the knowledge that there is enhanced amount of IL-2 in the sarcoid lung, but accumulation of only Leu3+ cells, suggests that the stimulus that activates these cells is Leu3+ specific. In support of this concept, several studies have documented that certain classes of antigens are helper/inducer subset-specific. Interestingly, in berylliosis as well, the intradermal injection ofberyllium salts determines a selective accumulation of Leu3+ cells surrounding newly formed granulomas (65), consistent with in vitro observations of Meuer et al. (50) , that responses to certain classes of antigens may be T cell type-specific. Interestingly, the fact that sarcoid patients respond to intradermal injection of the Kveim-Siltzbach antigen (a suspension ofan extract ofsarcoid spleen) by producing granulomas surrounded by Leu3+ T cells (66) is consistent with concept that such suspensions may contain a class of antigens that specifically activate the Leu3+ T cell subtype.
Thirdly, the observations in the sarcoid lung are also consistent with the hypothesis that the disease is associated with a loss of the normal suppressor processes such that normal antigenic stimuli are not normally dampened, thus permitting an overexuberant helper/inducer T cell response (67) .
Finally, it is conceivable that sarcoid represents an infectious disorder in which the causative agent is trophic for Leu4+Leu3+ lymphocytes, causing them to proliferate and release IL-2. In this regard, whereas HTLV-I and HTLV-III retrovirus infections are models for T cell-specific accumulation or loss, respectively (68) , studies in sarcoid lung T cells have failed to reveal reverse transcriptase or specific evidence of HTLV-I (69), the closest retrovirus model for sarcoid.
Independent of the inciting mechanism, because IL-2 promotes the growth of activated lymphocytes, and because the sarcoid lung is dominated by Leu4+Leu3+ high-intensity DR lymphocytes, it is reasonable to conclude that the Leu4+Leu3+ high-intensity DR IL-2-releasing cells play a central role in the persistent accumulation of large numbers of T lymphocytes in the lower respiratory tract.
